Back
Sight Sciences
IPOSGHT.NASDAQPast

Sight Sciences

Medical device company

Company website ↗
Foundation year: 2011
Profitability
+33.83%
IPO date
14/07/2021

About

Total Funding

$108.7M


Sight Sciences is a medical device company that uses a computer-based device designed for the treatment of eye disease. Sight Sciences' devices and non-invasive dry eye products are used for glaucoma procedures or in combination with cataract surgery using the same clear corneal incision, assisting ophthalmologists and optometrists to address the underlying physiology of ophthalmic disease.

The company's non-surgical Dry Eye product portfolio consists of TearCare which is now commercially available for both ophthalmologists and optometrists. TearCare is a software-controlled, wearable eyelid technology that delivers highly targeted and adjustable heat to the meibomian glands of the eyelids for conditions such as meibomian gland dysfunction and dry eye.

It was founded in 2011 and is headquartered in Menlo Park, California, United States.


Number of employees

100-250


Headquarters

Menlo Park, California, United States

Underwriters

D1 Capital Partners, KCK, Allegro Investment Fund